Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Esa Jarkko Mikael Kari"'
Autor:
Peeter Karihtala, Milla E.L. Kuusisto, Outi Kuittinen, Anna E. Hakalahti, Taina Turpeenniemi-Hujanen, Kirsi-Maria Haapasaari, Jan Böhm, Hanna-Riikka Teppo, Esa Jarkko Mikael Kari
Publikováno v:
Anticancer Research. 39:4925-4931
BACKGROUND/AIM Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy where antioxidant enzyme peroxiredoxin 6 (Prx6) has previously been associated with adverse outcomes. Its systemic effects in DLBCL are unknown. MATERIALS AND METHODS Th
Autor:
Outi Kuittinen, Mikko C Chan, Milla E.L. Kuusisto, Hanne Kuitunen, Ilkka Miinalainen, Risto Pirinen, Janette Savela, Esa Jarkko Mikael Kari, Riina K Ollikainen, Hanna-Riikka Teppo, Taina Turpeenniemi-Hujanen
Publikováno v:
Oxidative Medicine and Cellular Longevity, Vol 2021 (2021)
Oxidative Medicine and Cellular Longevity
Oxidative Medicine and Cellular Longevity
DLBCL is the most common type of non-Hodgkin lymphoma with a substantial group of patients suffering a poor prognosis. Therefore more specific markers are required for better understanding of disease biology and treatment. This study demonstrates tha
Autor:
Taina Turpeenniemi-Hujanen, Milla E.L. Kuusisto, Anna E. Hakalahti, Risto Bloigu, Hanna-Riikka Teppo, Esa Jarkko Mikael Kari, Päivi Honkavaara, Peeter Karihtala, Outi Kuittinen, Kirsi-Maria Haapasaari, Risto Pirinen
Publikováno v:
European journal of haematologyREFERENCES. 105(2)
OBJECTIVE In diffuse large B-cell lymphoma (DLBCL), there is an unmet medical need to select patients who would benefit from intensified frontline treatments such as adding etoposide to an R-CHOP regimen. METHODS The present work included a retrospec
Autor:
Esa Jantunen, Esa Jarkko Mikael Kari, Taina Turpeenniemi-Hujanen, Outi Kuittinen, Aurora Lemma, Risto Pirinen, Hanna-Riikka Teppo, Ylermi Soini, Peeter Karihtala, Milla E.L. Kuusisto, Kirsi-Maria Haapasaari
Publikováno v:
Journal of Clinical Pathology
AimsOxidative stress markers and antioxidant enzymes have previously been shown to have prognostic value and associate with adverse outcome in patients with diffuse large B cell lymphoma (DLBCL). Nuclear factor erythroid 2-related factor 1 (Nrf1) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1c425ead0e9e732b2f05ac32819eba4
http://urn.fi/urn:nbn:fi-fe2019070122439
http://urn.fi/urn:nbn:fi-fe2019070122439